|
Burkitt Lymphoma
|
0.580 |
Biomarker
|
disease |
BEFREE |
Strikingly, we did not detect recurrent mutations in genes of the ID3-TCF3 axis or the SWI/SNF complex that are frequently altered in BL, or in genes frequently mutated in germinal center-derived B-cell lymphomas like <i>KMT2D</i> or <i>CREBBP</i> An exception is <i>GNA13</i>, which was mutated in 7 of 15 cases.
|
30567752 |
2019 |
|
Burkitt Lymphoma
|
0.580 |
Biomarker
|
disease |
BEFREE |
A total of four TFs (E2F1, NFKB1, E2F4 and TCF3) exhibit complicated regulation associations in BL-associated networks.
|
30127896 |
2018 |
|
Burkitt Lymphoma
|
0.580 |
Biomarker
|
disease |
BEFREE |
In conclusion, <i>ID3-TCF3-CCND3</i> pathway genes are mutated in more than 88% of <i>MYC</i>-rearranged pediatric B-cell non-Hodgkin lymphoma and the pathway may represent a highly relevant second hit of Burkitt lymphoma pathogenesis, especially in children and adolescents.
|
28209658 |
2017 |
|
Burkitt Lymphoma
|
0.580 |
AlteredExpression
|
disease |
BEFREE |
Since no definitive data are available on the genetic landscape of endemic Burkitt (eBL), we first assessed the mutation frequency of TCF3/ID3 in eBL compared with sBL and subsequently the somatic hypermutation status of the BCR to answer whether an extrinsic activation of BCR signaling could also be demonstrated in Burkitt lymphoma.
|
26712879 |
2016 |
|
Burkitt Lymphoma
|
0.580 |
Biomarker
|
disease |
BEFREE |
TCF-3 promotes antigen-independent (tonic) B-cell-receptor signaling in Burkitt lymphoma by transactivating immunoglobulin heavy- and light-chain genes while repressing PTPN6, which encodes the phosphatase SHP-1, a negative regulator of B-cell-receptor signaling.
|
24492847 |
2014 |
|
Burkitt Lymphoma
|
0.580 |
AlteredExpression
|
disease |
BEFREE |
In particular, mutations in the transcription factors ID3 and TCF3, leading to overexpression of B-cell receptor components such as VPREB3, have been shown to be specific for Burkitt lymphoma (BL) and play an important tumourigenic role by mediating the activation of the pro-survival phosphatidylinositol-3-OH kinase pathway.
|
24493312 |
2014 |
|
Burkitt Lymphoma
|
0.580 |
GeneticVariation
|
disease |
BEFREE |
Two studies in this issue identify the landscape of somatic mutations in Burkitt lymphoma and highlight the pathogenic and clinical relevance of inactivating mutations of ID3, an inhibitor of the TCF3 transcription factor.
|
23192177 |
2012 |
|
Burkitt Lymphoma
|
0.580 |
AlteredExpression
|
disease |
BEFREE |
TCF3 activated the pro-survival phosphatidylinositol-3-OH kinase pathway in BL, in part by augmenting tonic B-cell receptor signalling.
|
22885699 |
2012 |
|
Burkitt Lymphoma
|
0.580 |
Biomarker
|
disease |
CTD_human |
B-cell development fails in the absence of the Pbx1 proto-oncogene.
|
17244677 |
2007 |
|
Burkitt Lymphoma
|
0.580 |
Biomarker
|
disease |
CTD_human |
Chromosomal translocation t(1;19) results in synthesis of a homeobox fusion mRNA that codes for a potential chimeric transcription factor.
|
1967982 |
1990 |
|
Burkitt Lymphoma
|
0.580 |
FusionGene
|
disease |
ORPHANET |
|
|
|